Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test
May 27, 2021
We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021 2nd ODD granted as treatment for systemic sclerosis from the US FDA SEOUL, South Korea, May 27, 2021 /PRNewswire/ -- Daewoong Pharmaceutical of South Korea has announced the promising clinical results of DWN12088, which is being developed as a first-in-class Prolyl-tRNA Synthetase(PRS) inhibitor for i